Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994634 | 1.00 | CTSL (0.55) | CTSLCTSSMEN1KMT2ACTSB | |
| SCHEMBL15317912 | 1.00 | CTSL (0.55) | CTSLCTSSMEN1KMT2ACTSB | |
| SCHEMBL8150285 | 0.88 | TRPM8 (0.58) | CTSLCTSSMEN1KMT2AATM | |
| SCHEMBL12069024 | 0.88 | TRPM8 (0.58) | CTSLCTSSMEN1KMT2AATM | |
| SCHEMBL15312880 | 0.87 | HTT (0.44) | CTSLCTSSMEN1KMT2AATM | |
| SCHEMBL15312882 | 0.87 | HTT (0.44) | CTSLCTSSMEN1KMT2AATM | |
| SCHEMBL10806439 | 0.85 | CTSL (0.47) | CTSLCTSSMEN1KMT2ACTSB | |
| SCHEMBL9830841 | 0.85 | CTSL (0.54) | CTSLCTSSMEN1KMT2ACTSB | |
| SCHEMBL16587917 | 0.85 | CTSL (0.54) | CTSLCTSSMEN1KMT2ACTSB | |
| SCHEMBL9830850 | 0.85 | CTSL (0.54) | CTSLCTSSMEN1KMT2ACTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987504-B2 | Aminohydroxylation of alkenes | VICTORIA LINK LIMITED (NZ) | 2015-03-24 | — | — | US | disclosed |
| US-8987504-B2 | Aminohydroxylation of alkenes | VICTORIA LINK LIMITED (NZ) | 2015-03-24 | — | — | US | disclosed |
| US-20130274479-A1 | AMINOHYDROXYLATION OF ALKENES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2013-10-17 | — | — | US | disclosed |
| US-20130274479-A1 | AMINOHYDROXYLATION OF ALKENES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2013-10-17 | — | — | US | disclosed |
| WO-2011159177-A1 | IMPROVED AMINOHYDROXYLATION OF ALKENES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274479-A1 | AMINOHYDROXYLATION OF ALKENES | ALKBH3, ALKBH1, ALKBH2 | CTSL 1494/4885CTSS 2286/4885MEN1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.